Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

Study Overview

• Status: Recruiting
• Conditions: Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
• Intervention / Treatment: Drug: Cadonilimab Injection; Drug: Ramucirumab Injection

Detailed Description

An open, single-arm, single-centre,Phase II clinical study evaluating Cadonilimab in combination with Ramucirumab for the treatment of advanced hepatocellular carcinoma that has failed at systemic therapy

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Huikai Li, MD; Phone Number: 18622228639; Email: tjchlhk@126.com
• Study Contact Backup: Name: Yang Liu, MD; Phone Number: 17694950696

Study Locations

• China
  • Tianjin
    • Tianjin, Tianjin, China, 300308
      • Recruiting
      • Tianjin Cancer hospital Airport hospital
      • Contact: Huikai Li, MD; Phone Number: 18622228639; Email: tjchlhk@126.com
      • Contact: Yang Liu, MD; Phone Number: 17694950696

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. written informed consent signed prior to enrolment.
2. age > 18 years, both sexes
3. patients with histologically or pathologically confirmed intermediate to advanced hepatocellular carcinoma.
4. Previously received systemic drug treatment for HCC, with disease progression or intolerable toxicity
5. Child-Pugh A or B7
6. with measurable lesions (≥10 mm long diameter on CT scan for non-lymph node lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria).
7. ECOG PS score: 0 to 1.
8. expected survival of >12 weeks.
9. function of vital organs in accordance with the following requirements (excluding the use of any blood components and cell growth factors within 14 days).

1) Blood count. Neutrophils ≥ 1.5 x 109/L Platelet count ≥ 60×109/L haemoglobin ≥ 90 g/L. 2) Liver and kidney function. Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula).

total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN) Glutamic aminotransferase (AST) or glutamic aminotransferase (ALT) levels ≤ 10 times the upper limit of normal (ULN); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification must show ≤ 1 g of protein.

10. normal coagulation function, no active bleeding or thrombotic disease

1. International normalised ratio INR ≤ 1.5 x ULN.
2. partial thromboplastin time APTT ≤ 1.5 x ULN.
3. prothrombin time PT ≤ 1.5 x ULN. 11. Female patients who are non-surgically sterilised or of childbearing age are required to use a medically approved contraceptive (e.g. IUD, pill or condom) during and for 3 months after the end of the study treatment period; female patients of childbearing age who are non-surgically sterilised must have a negative serum or urine HCG test within 7 days prior to study entry; and must be non-lactating; male patients who are non-surgically sterilised or of childbearing age Patients, need to agree to use a medically approved form of contraception with their spouse during and for 3 months after the end of the study treatment period.

12. The subject is voluntarily enrolled in the study, is compliant and cooperates with safety and survival follow-up

Exclusion Criteria:

Patients with any of the following are not eligible for enrollment in this study.

1. Subjects with previous or concurrent other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).
2. the subject has received previous immunotherapy other than anti-PD-1/PD-L1 monoclonal antibody; the subject is known to have a previous allergy to macromolecular protein agents, or is known to be allergic to the components of the drug applied.
3. The subject has any active autoimmune disease or history of autoimmune disease (e.g. the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, previous thyroid surgery cannot be included; the subject has vitiligo or has complete remission of asthma in childhood and in adulthood (subjects who do not require any intervention can be included; subjects with asthma requiring medical intervention with bronchodilators cannot be included).
4. subjects who are on immunosuppressive, or systemic, or absorbable topical hormone therapy for immunosuppressive purposes (doses >10 mg/day of prednisone or other isotonic hormones) and who continue to use them within 2 weeks prior to enrolment
5. have clinically symptomatic ascites or pleural effusion requiring therapeutic puncture or requiring frequent drainage of ascites (≥1 time/month)
6. subjects with clinically symptomatic cardiac conditions or diseases that are not well controlled, such as (1) NYHA class 2 or higher heart failure (2) unstable angina pectoris (3) previous myocardial infarction within 1 year (4) patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
7. subjects with active infection or unexplained fever >38.5 degrees during screening and prior to the first dose (subjects with fever arising from a tumour may be enrolled, as judged by the investigator)
8. patients with previous and current objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severely impaired lung function
9. subjects with congenital or acquired immune deficiency, e.g. HIV infection
10. subjects who have received a live vaccine less than 4 weeks prior to study drug administration or possibly during the study period
11. subjects with a known history of psychotropic substance abuse, alcoholism or drug use
12. patients who are unable to administer the drug orally
13. have received herbal or proprietary Chinese medicine with an anti-tumour indication within 2 weeks prior to the first dose .

14 Patients who, in the opinion of the investigator, should be excluded from the study, for example, subjects who, in the judgment of the investigator, have other factors that may force the study to be terminated, e.g., other serious illnesses (including psychiatric illnesses) requiring comorbid treatment, severe fundic esophageal varices, serious laboratory test abnormalities, accompanying family or social factors that would compromise the safety of the subject, or the collection of data and samples.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cadonilimab in Combination With Ramucirumab; Cadonilimab Injection 10mg/kg, intravenous drip ,q2w,	Drug: Cadonilimab Injection; Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,; Other Names: AK104; Drug: Ramucirumab Injection; Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	OS is defined as the time from date of neoadjuvant treatment start to the date of death from any cause or to the date of last follow-up if patients are alive. If a patient is alive by the time of final analysis, the patient will be censored at the last follow-up date.	up to 3 years
Progress Free Survival （PFS）	Defined as the time from enrollment to disease progression or death (whichever occurs first)	up to 3 years
Overall response rate (ORR)	Defined as proportion of patients who have a best response of CR or PR	up to 1 years
Adverse Events（AEs）	Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0	up to 3 years

Collaborators and Investigators

• Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Investigators: Study Director: Huikai Li, MD, Tianjin Cancer hospital Airport hospital

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2024
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): May 1, 2025

Study Registration Dates

• First Submitted: May 4, 2023
• First Submitted That Met QC Criteria: May 4, 2023
• First Posted (Actual): May 12, 2023

Study Record Updates

• Last Update Posted (Estimated): April 15, 2024
• Last Update Submitted That Met QC Criteria: April 11, 2024
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ramucirumab
• Other Study ID Numbers: AK104-IIT-C-N1-0042

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No